CH EPL (R5)
0.1.0 - ci-build

CH EPL (R5), published by Federal Office of Public Health FOPH. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/bag-epl/bag-epl-fhir/ and changes regularly. See the Directory of published versions

Example RegulatedAuthorization: Reimbursement SL 21529

Generated Narrative: RegulatedAuthorization FOPH-21529

CH - EPL Reimbursement SL

  • FOPHDossierNumber: urn:oid:2.16.756.1/21529
  • status: Reimbursed
  • statusDate: 2023-12-01
  • expiryDate: 2026-03-31
  • listingStatus: Listed
  • listingPeriod: 2023-12-01 --> 2025-12-31
  • firstListingDate: 2023-12-01
  • costShare: 10
  • gamme: Oral

CH - EPL Product Price

  • value: CHF958.62 (CHF)
  • type: Ex-factory price
  • changeType: Price mutation after triennal review of pharmaceuticals
  • changeDate: 2023-12-01

CH - EPL Product Price

  • value: CHF1,113.95 (CHF)
  • type: Retail price
  • changeType: VAT-change
  • changeDate: 2024-01-01

subject: PackagedProductDefinition: identifier = http://SMC.ch/ig/idmp/NamingSystem/IDSystem-ch-PCID#CH-7601001010604-6879301-001; containedItemQuantity = 30 Tablet; description = PAXLOVID Filmtabl 4x150mg/2x100mg

type: Reimbursement SL

Indications

-ExtensionReference
*ClinicalUseDefinition: type = indication

holder: Organization Pfizer AG

Generated Narrative: Organization #holder-Pfizer-AG

identifier: urn:oid:1.2.276.0.76/100015286, GLN/7601001010604

name: Pfizer AG